

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- | | | |
|-------------------------------------|-------------------------------------|--|
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | The statistical test(s) used AND whether they are one- or two-sided
<i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i> |
| <input type="checkbox"/> | <input type="checkbox"/> | A description of all covariates tested |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| <input type="checkbox"/> | <input type="checkbox"/> | For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
<i>Give P values as exact values whenever suitable.</i> |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| <input type="checkbox"/> | <input type="checkbox"/> | Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated |

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	No custom or commercial software was used for data collection. Clinical observations were recorded manually. Molecular data (e.g., qPCR Ct values) were exported using Agilent AriaMx software version 1.7
Data analysis	Data analysis was performed using Python version 3.13. The following open-source libraries were used: pandas (data manipulation), scipy (statistical testing), matplotlib and seaborn (data visualization). For sequence analysis and genome assembly, CLC Genomics Workbench versions 23 and 24 (Qiagen Digital Insights) were used. Phylogenetic analyses were conducted using MegAlign Pro (DNASTAR Lasergene v18.0.1) and RAXML (Maximum Likelihood method).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The complete genome sequences of ParPgV-A and ParPgV-C have been deposited in the NCBI GenBank under accession numbers PV472371 and PV472372,

respectively. The data are kept confidential until the publication of the manuscript, but can be provided to the reviewers if required.

All other data supporting the findings of this study, including viral load measurements, histopathology evaluations, statistical source data, primers, probes, cycling conditions, and amino acid identity matrix, are available within the manuscript and its supplementary files or from the corresponding author upon request.

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender

Reporting on race, ethnicity, or other socially relevant groupings

Population characteristics

Recruitment

Ethics oversight

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

Data exclusions

Replication

Randomization

Blinding

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms
<input type="checkbox"/>	<input type="checkbox"/> Clinical data
<input type="checkbox"/>	<input type="checkbox"/> Dual use research of concern
<input type="checkbox"/>	<input type="checkbox"/> Plants

Methods

n/a	Involved in the study
<input type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input type="checkbox"/>	<input checked="" type="checkbox"/> MRI-based neuroimaging

Antibodies used

A custom rabbit polyclonal antibody was generated against the ParPgV-A envelope glycoprotein E2 (amino acids 414–570). The recombinant protein was expressed using the Bac-to-Bac Baculovirus system (Invitrogen) and purified via His-tag affinity chromatography (His GraviTrap™ TALON®, Cytiva, Marlborough, MA, USA). Polyclonal antibody production was outsourced to Davids Biotechnologie GmbH (Regensburg, Germany).
Primary antibody used: Rabbit anti-ParPgV E2 polyclonal serum (custom-made; no catalog number; dilution 1:500 for immunohistochemistry).
Secondary antibody: Biotinylated anti-rabbit IgG (Vector Laboratories, Burlingame, USA); used at 1:400 dilution.

Antibodies

Validation

The antibody was validated in-house using formalin-fixed paraffin-embedded (FFPE) tissue from field-infected red-legged partridges and experimental animals. Specificity was confirmed by negative staining in tissues from uninfected SPF chickens and red-legged partridges, as well as birds infected with unrelated pathogens (e.g., fowl adenovirus, *Histomonas meleagridis*). Signal specificity and background were optimized using three different dilutions (1:100, 1:500, 1:1000), and 1:500 was selected based on optimal staining intensity and minimal background. Validation data are presented in the manuscript (Fig. 7 and 8).

Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

Cell line source(s)

Not applicable.

Authentication

Not applicable.

Mycoplasma contamination

Not applicable.

Commonly misidentified lines (See [ICLAC](#) register)

Not applicable.

Palaeontology and Archaeology

Specimen provenance

Not applicable.

Specimen deposition

Not applicable.

Dating methods

Not applicable.

☐ Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

Ethics oversight

Not applicable.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Animals and other research organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

Laboratory animals

This study involved three species of birds housed under controlled laboratory conditions:

- Red-legged partridges (*Alectoris rufa*), 5-month-old, obtained as embryonated eggs from a commercial supplier (Gibovendé, France).
- Grey partridges (*Perdix perdix*), 5-month-old, obtained from a local Austrian supplier.
- Specific-pathogen-free (SPF) White Leghorn chickens (*Gallus gallus*), 4-week-old, obtained as embryonated eggs from VALO BioMedia GmbH (Osterholz-Scharmbeck, Germany).

Wild animals

The study did not involve wild animals. All birds were sourced commercially and raised under controlled conditions.

Reporting on sex

Sex was not a primary experimental variable and birds were not sexed prior to inoculation due to the practical difficulty of sexing juvenile birds and the limited number of individuals per group and time point. However, sexing was routinely performed during necropsy as part of the post-mortem protocol, and this information was recorded for all animals. Post hoc segregation of data by sex revealed no differences in viral load or pathological outcomes, although this may reflect the low sample size per sex at individual time points. Consequently, no sex-based analyses were performed in the main manuscript.

Field-collected samples

Field samples were obtained from three breeder flocks of red-legged partridges (*Alectoris rufa*) on two commercial farms in France experiencing outbreaks of neurological disease. Affected birds were culled by farm personnel based on clinical signs and submitted for diagnostic investigation. Post-mortem brain and organ tissues were collected and shipped to the University of Veterinary Medicine Vienna, Austria, for virological and histopathological analysis. These field-derived samples were used exclusively for diagnostic evaluation, histology, RNAscope, and genome characterization; they were not used for experimental inoculations. Additionally, no live animals were transported from field sites.

Ethics oversight

All animal procedures were reviewed and approved by the Ethics and Animal Welfare Committee of the University of Veterinary Medicine Vienna, Austria, and authorized by the Austrian Federal Ministry of Education, Science, and Research (approval numbers: BMBWF 2022-0.713.294 and Extension 2023-0.430.929).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration	Not applicable.
Study protocol	Not applicable.
Data collection	Not applicable.
Outcomes	Not applicable.

Dual use research of concern

Policy information about [dual use research of concern](#)

Hazards

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

No	Yes
<input checked="" type="checkbox"/>	<input type="checkbox"/> Public health
<input checked="" type="checkbox"/>	<input type="checkbox"/> National security
<input checked="" type="checkbox"/>	<input type="checkbox"/> Crops and/or livestock
<input checked="" type="checkbox"/>	<input type="checkbox"/> Ecosystems
<input checked="" type="checkbox"/>	<input type="checkbox"/> Any other significant area

Experiments of concern

Does the work involve any of these experiments of concern:

No	Yes
<input checked="" type="checkbox"/>	<input type="checkbox"/> Demonstrate how to render a vaccine ineffective
<input checked="" type="checkbox"/>	<input type="checkbox"/> Confer resistance to therapeutically useful antibiotics or antiviral agents
<input checked="" type="checkbox"/>	<input type="checkbox"/> Enhance the virulence of a pathogen or render a nonpathogen virulent
<input checked="" type="checkbox"/>	<input type="checkbox"/> Increase transmissibility of a pathogen
<input checked="" type="checkbox"/>	<input type="checkbox"/> Alter the host range of a pathogen
<input checked="" type="checkbox"/>	<input type="checkbox"/> Enable evasion of diagnostic/detection modalities
<input checked="" type="checkbox"/>	<input type="checkbox"/> Enable the weaponization of a biological agent or toxin
<input checked="" type="checkbox"/>	<input type="checkbox"/> Any other potentially harmful combination of experiments and agents

Plants

Seed stocks	Not applicable.
Novel plant genotypes	Not applicable.
Authentication	Not applicable.

ChIP-seq

Data deposition

- ☐ Confirm that both raw and final processed data have been deposited in a public database such as [GEO](#).
- ☐ Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links <i>May remain private before publication.</i>	Not applicable.
Files in database submission	Not applicable.

Genome browser session
(e.g. [UCSC](#))

Not applicable.

Methodology

Replicates

Not applicable.

Sequencing depth

Not applicable.

Antibodies

Not applicable.

Peak calling parameters

Not applicable.

Data quality

Not applicable.

Software

Not applicable.

Flow Cytometry

Plots

Confirm that:

- ☐ The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- ☐ The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- ☐ All plots are contour plots with outliers or pseudocolor plots.
- ☐ A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation

Not applicable.

Instrument

Not applicable.

Software

Not applicable.

Cell population abundance

Not applicable.

Gating strategy

Not applicable.

☐ Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

Magnetic resonance imaging

Experimental design

Design type

This study utilized a task-free, resting-state, longitudinal design with repeated MRI acquisitions at predefined time points (7, 10, 14, and 21 days post-infection). No task or stimulus was applied during MRI acquisition. Birds were under deep sedation, and imaging was conducted in a resting, non-responsive condition. The study did not use an event-related or block design.

Design specifications

Each bird underwent one MRI session per time point, with imaging performed at four defined time points: 7, 10, 14, and 21 days post-infection. The birds were under deep sedation during each session to minimize movement and stress. As this was a structural MRI study, not a task-based or functional MRI study, there were no experimental "blocks" or "trials" in the conventional sense.

Behavioral performance measures

Not applicable.

Acquisition

Imaging type(s)

Structural MRI study

Field strength

1.5 Tesla

Sequence & imaging parameters

T2-weighted CISS 3DT1-weighted TSE transverse T2-weighted TIR transverse T1-weighted GRE turbo flash 3D

Area of acquisition

Entire brain of the birds.

Diffusion MRI

☐ Used

☒ Not used

Preprocessing

Preprocessing software	Not applicable.
Normalization	Not applicable.
Normalization template	Not applicable.
Noise and artifact removal	Not applicable.
Volume censoring	Not applicable.

Statistical modeling & inference

Model type and settings	Not applicable. The evaluation of the MRI images was purely descriptive and based on qualitative assessment. No statistical modeling or inferential analysis was performed in this study.
Effect(s) tested	Not applicable. The evaluation of the MRI images was purely descriptive and based on qualitative assessment. No statistical modeling or inferential analysis was performed in this study.
Specify type of analysis:	<input checked="" type="checkbox"/> Whole brain <input type="checkbox"/> ROI-based <input type="checkbox"/> Both
Statistic type for inference (See Eklund et al. 2016)	Not applicable. The evaluation of the MRI images was purely descriptive and based on qualitative assessment. No statistical modeling or inferential analysis was performed in this study.
Correction	Not applicable. The evaluation of the MRI images was purely descriptive and based on qualitative assessment. No statistical modeling or inferential analysis was performed in this study.

Models & analysis

n/a	Involved in the study	
<input checked="" type="checkbox"/>	<input type="checkbox"/> Functional and/or effective connectivity	
<input checked="" type="checkbox"/>	<input type="checkbox"/> Graph analysis	
<input checked="" type="checkbox"/>	<input type="checkbox"/> Multivariate modeling or predictive analysis	